Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFF-R CAR-T in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
NCT07259070Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PMB-101 in B cell lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Maximum Tolerated Dose at Day 28. Started Nov 2025; status: recruiting.
02
Drugs
PMB-101
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07259070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259070.